Lumira Capital Investment Management Inc. 4
4 · Edesa Biotech, Inc. · Filed Jan 11, 2023
Insider Transaction Report
Form 4
van der Velden Peter
Director10% Owner
Transactions
- Sale
Common share
2023-01-09$2.66/sh−132,845$353,647→ 1,764,583 total(indirect: By IRA) - Sale
Common share
2023-01-09$2.66/sh−12,284$32,701→ 163,170 total(indirect: By IRA) - Sale
Common share
2023-01-10$2.63/sh−12,895$33,973→ 150,275 total(indirect: By IRA) - Sale
Common share
2023-01-10$2.63/sh−139,450$367,395→ 1,625,133 total(indirect: By IRA)
Footnotes (1)
- [F1]This Form 4 is jointly filed by (i) Lumira Capital II, L.P. ("LCII LP"), (ii) Lumira Capital II (International), L.P. ("LCII INT LP"), (iii) Lumira Capital GP, L.P., (iv) Lumira GP Inc. (v) Lumira GP Holdings Co., and (vi) Lumira Capital Investment Management Inc. Lumira Capital GP, L.P. the general partners of which are Lumira GP Inc. and Lumira GP Holdings Co., is the general partner of LCII LP and LCII INT LP, and each of LCII LP and LCII INT LP is managed by Lumira Capital Investment Management Inc. Mr. van der Velden is an executive officer of Lumira GP Inc., Lumira GP Holdings Co., and Lumira Capital Investment Management Inc. Each of Lumira Capital GP, L.P., Lumira GP Inc., Lumira GP Holdings Co., Lumira Capital Investment Management Inc. and Mr. van der Velden may be deemed to beneficially own the shares held by LCII LP and LCII INT LP, but each disclaim beneficial ownership except to the extent of their pecuniary interest therein, if any.